Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19 in Washington, D.C. Accepted abstracts and the full preliminary program is available on the ASGCT website.

“We look forward to reporting data at ASGCT 2022 that showcases our broad range of gene therapy expertise that is shaping our portfolio strategy and therapeutic pipeline,” said Al Sandrock, M.D., Ph.D., CEO of Voyager Therapeutics. “Among the notable findings to be presented are new data from Voyager’s TRACER™ AAV capsids, including a novel AAV9-derived capsid family with tropism for glial cells, updated findings from our novel vectorized antibody approach designed to activate innate immune system to destroy metastatic breast cancer tumors, and results from our Tau, SOD1 ALS, and GBA1 programs.”

Details for the oral and poster presentations are as follows.

Oral Presentations

Monday, May 16

CNS Penetrant AAV Vectors Encoding HER2 Antibodies Reduce Tumor Burden in Models of Breast Cancer Brain Metastasis
Dan Laks, Ph.D., Senior Scientist I, Program Lead
Summary: A CNS-targeted, TRACER-generated AAV capsid was used to deliver broad brain expression of a vectorized HER2 antibody, which activated the innate immune response with increased tumor-proximal natural killer cells, proliferating microglia, and dendritic cells, and significantly reduced tumor burden in multiple mouse models.
Session: AAV Preclinical CNS Gene Therapy
Location & Time: Room 204, 5:15 p.m. – 5:30 p.m. EST
Abstract Number: 63

Thursday, May 19

Directed Evolution of AAV9 Peptide Display Libraries Identifies a Family of Cross-Species Variants with Enhanced Brain Tropism in Non-Human Primates and Mice Following Systemic Administration
Tyler Moyer, Ph.D., Scientist II, Capsid Discovery
Summary: A novel, TRACER-generated AAV9 capsid family achieved 50-fold better transduction in mice and 60-fold better transduction in macaques compared to conventional AAV9 with a unique tropism for glial cells.
Session: Novel AAV Capsids for the Brain, Eye and Kidney
Location & Time: Ballroom A, 11:00 a.m. – 11:15 a.m. EST
Abstract number: 1198

Poster Presentations

All posters will be presented in Hall D, 5:30 p.m. – 6:30 p.m. EST.

Monday, May 16

Directed Evolution of an AAV5 Capsid Library Identifies a Variant with Enhanced Transduction in Non-Human Primate and Rodent Brain Following Systemic Administration
Mathieu Nonnenmacher, Ph.D., Vice President, Capsid Discovery
Session: AAV Vectors - Virology and Vectorology I
Poster Board Number: M-10
Abstract Number: 129

Development of High Throughput Screening for DOE-Based Formulation Screening
Robert Vass, Ph.D., Senior Scientist I, Technical Operations

Session: Pharmacology/Toxicology Studies or Assay Development I
Poster Board Number: M-303
Abstract number: 422

Forced Degradation Studies of AAVs to Generate the Full Spectrum Aggregation Toolkit
Ariel Velez, Ph.D., Scientist I, Technical Operations
Session: Vector Product Engineering, Development or Manufacturing I
Poster Board Number: M-269
Abstract number: 388

Tuesday, May 17, 2022

Development of AAV-GBA1 Gene Replacement Therapy for IV Delivery via Blood Brain Barrier Penetrant AAV Capsid
Charlotte Chung, Ph.D., Associate Director, Research
Session: Gene Targeting and Gene Correction II
Poster Board Number: Tu-71
Abstract number: 566

Structural Analysis of AAV9 Derivatives Produced on Different Production Platforms and Characterization of their Empty Capsids
Matteo Placidi, Ph.D., Associate Director, Analytical Sciences
Session: Vector Product Engineering, Development or Manufacturing II
Poster Board Number: Tu-247
Abstract number: 742

Wednesday, May 18, 2022

Efficacy of a Novel Vectorized Antibody Targeting the C-Terminal Domain of Tau Using Systemic Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mouse Models of Tauopathies
Wencheng Liu, Ph.D., Research Fellow
Session: Neurologic Diseases III
Poster Board Number: W-157
Abstract number: 1031

Intravenous Delivery of AAV Gene Therapy Provides Broad SOD1 Knockdown in the Spinal Cord and Robust Efficacy in a Mouse Model of SOD1-ALS
Michael Grannan, Ph.D., Senior Scientist II, Research

Session: Musculo-skeletal Diseases
Poster Board Number: W-187
Abstract number: 1061

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company’s TRACER discovery platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.      voyagertherapeutics.com      LinkedIn      Twitter

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.
For example, all statements Voyager makes regarding the participation of scientists associated with Voyager making presentations at ASGCT 2022, and the presentations of data at ASGCT 2022, the potential for capsids generated by Voyager’s TRACER capsid discovery technology to have a positive impact for gene therapy development and the treatment of patients with medical conditions; and the ability to broaden the application of Voyager’s TRACER platform and establish human proof-of-concept across a range of serious diseases, are forward looking statements.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the final acceptance by the organizers of ASGCT 2022 of submissions presenting Voyager research; the ability of Voyager scientists to effectively deliver their presentations at ASGCT 2022; the continued development by Voyager of various technology platforms, including the TRACER platform; and Voyager’s scientific approach and general development progress.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts
Investors:        
investors@voyagertherapeutics.com  

Media:
Scott Santiamo
ssantiamo@vygr.com 

Peg Rusconi
prusconi@vergescientific.com 


Primary Logo

Back to news